uric acid has been researched along with Asymptomatic Conditions in 51 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In Japanese patients with asymptomatic hyperuricemia, 24 months of febuxostat treatment did not delay carotid atherosclerosis progression, compared with non-pharmacological care." | 9.34 | Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. ( Eguchi, K; Higashi, Y; Ishibashi, R; Ishizaka, N; Ishizu, T; Kanzaki, Y; Kario, K; Kato, T; Maemura, K; Murohara, T; Node, K; Ohishi, M; Oyama, JI; Sata, M; Sezai, A; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S; Yamada, H; Yokote, K, 2020) |
| "Allopurinol lowers uric acid and improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia." | 9.20 | Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia. ( Afsar, B; ALanaspa, M; Bakan, A; Elcioglu, OC; Erek, A; Johnson, RJ; Kanbay, M; Kostek, O; Mutlu, HH; Odabas, AR; Ozkok, A; Semerci, A; Sharma, S; Smits, G; Takir, M; Telci, O, 2015) |
| " allopurinol was associated with the improved safety outcome and have comparable mortality and net clinical outcome in patients with hyperuricemia." | 9.01 | The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis. ( Chang, WC; Chen, TC; Hsu, FS; Hwang, JJ; Lee, CC; Liu, CW; Lo, C; Shau, WY; Wang, ML, 2019) |
| "In patients with gout, treating to target serum uric acid levels (sUA) of ≤6." | 8.02 | Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021) |
| " This study was designed to evaluate the influences of long-term xanthine oxidase inhibitor (febuxostat) prescription on left ventricular hypertrophy (LVH), left ventricular (LV) diastolic function, and new-onset heart failure with preserved ejection fraction (HFpEF) in these patients." | 7.96 | Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia. ( Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF, 2020) |
| "Whether elevated uric acid (UA) is associated with silent myocardial infarction (SMI) or whether their joint association predicts an increased risk of mortality has not been explored." | 7.91 | Interrelations Between Serum Uric Acid, Silent Myocardial Infarction, and Mortality in the General Population. ( Ahmad, MI; Anees, MA; Dutta, A; Soliman, EZ, 2019) |
| "Moderately elevated serum uric acid levels are associated with an increased prevalence of any cardiac conduction defects in hospitalized patients with T2DM, independent of multiple risk factors and potential confounding variables." | 7.85 | Relation of elevated serum uric acid levels to first-degree heart block and other cardiac conduction defects in hospitalized patients with type 2 diabetes. ( Bonapace, S; Bonora, E; Dugo, C; Mantovani, A; Morani, G; Pichiri, I; Rigolon, R; Targher, G; Zoppini, G, 2017) |
| "Ursodeoxycholic acid (UDCA) is currently the only available pharmacological treatment for asymptomatic primary biliary cirrhosis (aPBC)." | 7.79 | Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. ( Dohmen, K; Haruno, M; Tanaka, H, 2013) |
| "Serum uric acid (SUA) is a suggested biomarker for established coronary artery disease, but the role of SUA in early phases of atherosclerosis is controversial." | 7.78 | Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study. ( Hutri-Kähönen, N; Huupponen, R; Jula, A; Juonala, M; Kähönen, M; Lehtimäki, T; Loo, BM; Lyytikäinen, LP; Oikonen, M; Raitakari, OT; Saarikoski, L; Seppälä, I; Siitonen, N; Viikari, JS; Wendelin-Saarenhovi, M, 2012) |
| "In Japanese patients with asymptomatic hyperuricemia, 24 months of febuxostat treatment did not delay carotid atherosclerosis progression, compared with non-pharmacological care." | 5.34 | Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. ( Eguchi, K; Higashi, Y; Ishibashi, R; Ishizaka, N; Ishizu, T; Kanzaki, Y; Kario, K; Kato, T; Maemura, K; Murohara, T; Node, K; Ohishi, M; Oyama, JI; Sata, M; Sezai, A; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S; Yamada, H; Yokote, K, 2020) |
| "Asymptomatic hyperuricemia is not a current indication for therapy as the definite role of serum uric acid elevation as a cardiovascular risk factor is extremely likely but still controversial." | 5.22 | Effects of a Novel Fixed Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid Profile in Asymptomatic Hyperuricemic Patients : Results from the PICONZ-UA Study. ( Ferri, C; Grassi, D; Izzo, R; Rozza, F; Trimarco, V, 2016) |
| "Allopurinol lowers uric acid and improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia." | 5.20 | Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia. ( Afsar, B; ALanaspa, M; Bakan, A; Elcioglu, OC; Erek, A; Johnson, RJ; Kanbay, M; Kostek, O; Mutlu, HH; Odabas, AR; Ozkok, A; Semerci, A; Sharma, S; Smits, G; Takir, M; Telci, O, 2015) |
| "Treatment of hyperuricemia with allopurinol improves endothelial dysfunction and eGFR in subjects with asymptomatic hyperuricemia." | 5.15 | A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. ( Azak, A; Covic, A; Duranay, M; Huddam, B; Johnson, RJ; Kadioglu, GK; Kanbay, M; Kirbas, I; Solak, Y, 2011) |
| " allopurinol was associated with the improved safety outcome and have comparable mortality and net clinical outcome in patients with hyperuricemia." | 5.01 | The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis. ( Chang, WC; Chen, TC; Hsu, FS; Hwang, JJ; Lee, CC; Liu, CW; Lo, C; Shau, WY; Wang, ML, 2019) |
| "In patients with gout, treating to target serum uric acid levels (sUA) of ≤6." | 4.02 | Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan. ( Horiuchi, H; Koto, R; Nakajima, A; Yamanaka, H, 2021) |
| " This study was designed to evaluate the influences of long-term xanthine oxidase inhibitor (febuxostat) prescription on left ventricular hypertrophy (LVH), left ventricular (LV) diastolic function, and new-onset heart failure with preserved ejection fraction (HFpEF) in these patients." | 3.96 | Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia. ( Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF, 2020) |
| "This study investigated the association of serum uric acid (UA) with carotid fluoro-2-deoxyglucose (FDG) uptake as a marker of inflammatory atherosclerosis." | 3.96 | Serum uric acid in asymptomatic adults is weakly associated with carotid artery FDG uptake but not intima-media thickness. ( Bae, JH; Cho, YS; Choi, JY; Hyun, SH; Kim, BT; Lee, KH; Moon, SH, 2020) |
| "Because the serum uric acid level increases as the glomerular filtration rate (GFR) decreases, hyperuricemia is associated with chronic kidney disease (CKD)." | 3.91 | Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function. ( Jeon, HJ; Oh, J; Shin, DH, 2019) |
| "Whether elevated uric acid (UA) is associated with silent myocardial infarction (SMI) or whether their joint association predicts an increased risk of mortality has not been explored." | 3.91 | Interrelations Between Serum Uric Acid, Silent Myocardial Infarction, and Mortality in the General Population. ( Ahmad, MI; Anees, MA; Dutta, A; Soliman, EZ, 2019) |
| " Serum uric acid (SUA) level and other clinical parameters were measured and hyperuricemia was defined as SUA level greater or equal to 360 umol/L in females and 420 umol/L in males." | 3.88 | Hyperuricemia in Asian psoriatic arthritis patients. ( Lai, TL; Leung, MC; Ng, WL; Wong, PY; Yim, CW, 2018) |
| "Moderately elevated serum uric acid levels are associated with an increased prevalence of any cardiac conduction defects in hospitalized patients with T2DM, independent of multiple risk factors and potential confounding variables." | 3.85 | Relation of elevated serum uric acid levels to first-degree heart block and other cardiac conduction defects in hospitalized patients with type 2 diabetes. ( Bonapace, S; Bonora, E; Dugo, C; Mantovani, A; Morani, G; Pichiri, I; Rigolon, R; Targher, G; Zoppini, G, 2017) |
| "In this cross-sectional study, consecutive inpatients with a non-ST elevation acute coronary event and asymptomatic hyperuricemia (serum uric acid concentration of ≥7." | 3.83 | Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study. ( Andrés, M; Pascual, E; Quintanilla, MA; Ruiz-Nodar, JM; Sánchez-Payá, J; Sivera, F; Vela, P, 2016) |
| "The aim of this study is to evaluate the diagnostic yield of dual-energy computed tomography (DECT) in detection of uric acid accumulation in joints or periarticular structures in patients suspected of having gout, in their intercritical period." | 3.83 | Dual-energy computed tomography as a diagnostic tool for gout during intercritical periods. ( Bogot, N; Breuer, GS; Nesher, G, 2016) |
| "Ursodeoxycholic acid (UDCA) is currently the only available pharmacological treatment for asymptomatic primary biliary cirrhosis (aPBC)." | 3.79 | Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. ( Dohmen, K; Haruno, M; Tanaka, H, 2013) |
| "Serum uric acid (SUA) is a suggested biomarker for established coronary artery disease, but the role of SUA in early phases of atherosclerosis is controversial." | 3.78 | Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study. ( Hutri-Kähönen, N; Huupponen, R; Jula, A; Juonala, M; Kähönen, M; Lehtimäki, T; Loo, BM; Lyytikäinen, LP; Oikonen, M; Raitakari, OT; Saarikoski, L; Seppälä, I; Siitonen, N; Viikari, JS; Wendelin-Saarenhovi, M, 2012) |
| " Subjects were further categorized into 3 diagnostic groups: gout, asymptomatic hyperuricemia (no gout, serum uric acid [UA] ≥6." | 3.77 | Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. ( Gyftopoulos, S; Howard, RG; Pillinger, MH; Samuels, J; Swearingen, CJ; Thiele, RG, 2011) |
| "Gout has been academically considered to be a step-up disease consisting of different stages: acute gout, intercritical gout, and chronic gout." | 2.50 | Clinical manifestations and diagnosis of gout. ( Castillo, E; Chinchilla, SP; Herrero-Beites, AM; Perez-Ruiz, F, 2014) |
| "Median time to recurrence was 64 months." | 1.56 | Predictive Factors for Kidney Stone Recurrence in Type 2 Diabetes Mellitus. ( Monga, M; Prasanchaimontri, P, 2020) |
| "Although hyperuricemia is associated with congestive heart failure (CHF), hyperuricemic patients frequently have other comorbidities." | 1.56 | Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities. ( Cheng, H; Jian, G; Tang, Y; Wang, N; Wu, J; Wu, X, 2020) |
| "Coronary atherosclerotic plaques (calcified, mixed, and non-calcified plaques) were assessed using CCTA." | 1.51 | Serum uric acid level and subclinical coronary atherosclerosis in asymptomatic individuals: An observational cohort study. ( Choe, J; Choi, SW; Hong, S; Kang, JW; Kim, HK; Kim, YG; Kim, YH; Lee, CK; Lee, SW; Lee, Y; Lim, DH; Lim, TH; Park, GM; Yang, DH; Yoo, B, 2019) |
| "Hyperuricemia has been associated with an increased risk of comorbidities such as metabolic syndrome or cardiovascular diseases." | 1.48 | The association between serum uric acid and asymptomatic intracranial arterial stenosis in middle-aged Koreans. ( Ahn, JK; Chung, PW; Hwang, J; Hwang, JH; Ryu, S; Yoon, WT, 2018) |
| "Uric acid level was significantly different between women with and without increased arterial stiffness, but not in men." | 1.40 | High uric acid level associated with increased arterial stiffness in apparently healthy women. ( Chang, CJ; Fang, JI; Lu, FH; Wang, RH; Wu, JS; Yang, YC, 2014) |
| "Gout was diagnosed at the last visit in 34 subjects; four in the normouricemia group and 30 in the hyperuricemia group (0." | 1.40 | The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort. ( Cohen, E; Duskin-Bitan, H; Garty, M; Goldberg, E; Krause, I; Levi, A; Shochat, T, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 39 (76.47) | 24.3611 |
| 2020's | 12 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, AR | 1 |
| Lee, SY | 1 |
| Joosten, LAB | 1 |
| Crişan, TO | 1 |
| Bjornstad, P | 1 |
| Johnson, RJ | 3 |
| Wu, X | 1 |
| Jian, G | 1 |
| Tang, Y | 1 |
| Cheng, H | 1 |
| Wang, N | 1 |
| Wu, J | 2 |
| Tanaka, A | 1 |
| Taguchi, I | 1 |
| Teragawa, H | 1 |
| Ishizaka, N | 1 |
| Kanzaki, Y | 1 |
| Tomiyama, H | 1 |
| Sata, M | 1 |
| Sezai, A | 1 |
| Eguchi, K | 1 |
| Kato, T | 1 |
| Toyoda, S | 1 |
| Ishibashi, R | 1 |
| Kario, K | 1 |
| Ishizu, T | 1 |
| Ueda, S | 1 |
| Maemura, K | 1 |
| Higashi, Y | 1 |
| Yamada, H | 1 |
| Ohishi, M | 1 |
| Yokote, K | 1 |
| Murohara, T | 1 |
| Oyama, JI | 1 |
| Node, K | 1 |
| Prasanchaimontri, P | 1 |
| Monga, M | 1 |
| Pan, JA | 1 |
| Lin, H | 1 |
| Wang, CQ | 1 |
| Zhang, JF | 1 |
| Gu, J | 1 |
| Sung, KT | 1 |
| Lo, CI | 1 |
| Lai, YH | 1 |
| Tsai, JP | 1 |
| Yun, CH | 1 |
| Hsiao, CC | 1 |
| Kuo, JY | 1 |
| Hou, CJ | 1 |
| Hung, TC | 1 |
| Su, CH | 1 |
| Hung, CL | 1 |
| Yeh, HI | 1 |
| Cauwenberghs, N | 1 |
| Sabovčik, F | 1 |
| Vandenabeele, E | 1 |
| Kobayashi, Y | 1 |
| Haddad, F | 1 |
| Budts, W | 1 |
| Kuznetsova, T | 1 |
| Kobalava, ZD | 1 |
| Troitskaya, EA | 1 |
| Cao, L | 1 |
| Zhao, T | 1 |
| Xie, C | 1 |
| Zheng, S | 1 |
| Wan, W | 1 |
| Zou, H | 1 |
| Zhu, X | 1 |
| Koto, R | 1 |
| Nakajima, A | 1 |
| Horiuchi, H | 1 |
| Yamanaka, H | 1 |
| Handa, R | 1 |
| Malaviya, AN | 1 |
| Kim, H | 1 |
| Kim, SH | 1 |
| Choi, AR | 1 |
| Kim, S | 1 |
| Choi, HY | 1 |
| Kim, HJ | 1 |
| Park, HC | 1 |
| Mantovani, A | 1 |
| Rigolon, R | 1 |
| Pichiri, I | 1 |
| Morani, G | 1 |
| Bonapace, S | 1 |
| Dugo, C | 1 |
| Zoppini, G | 1 |
| Bonora, E | 1 |
| Targher, G | 1 |
| Ahn, JK | 1 |
| Hwang, J | 1 |
| Hwang, JH | 1 |
| Yoon, WT | 1 |
| Chung, PW | 1 |
| Ryu, S | 1 |
| Salinas, M | 1 |
| López-Garrigós, M | 1 |
| Flores, E | 1 |
| Leiva-Salinas, C | 1 |
| Lai, TL | 1 |
| Yim, CW | 1 |
| Wong, PY | 1 |
| Leung, MC | 1 |
| Ng, WL | 1 |
| Zhou, G | 1 |
| Holzman, C | 1 |
| Luo, Z | 1 |
| Margerison, C | 1 |
| Bellomo, G | 1 |
| Selvi, A | 1 |
| Tamayo Y Orozco, JA | 1 |
| Estevez-Garcia, IO | 1 |
| Gallegos-Nava, S | 1 |
| Vera-Pérez, E | 1 |
| Silveira, LH | 1 |
| Ventura-Ríos, L | 1 |
| Vancini, G | 1 |
| Hernández-Díaz, C | 1 |
| Sánchez-Muñoz, F | 1 |
| Ballinas-Verdugo, MA | 1 |
| Gutierrez, M | 1 |
| Pineda, C | 1 |
| Rodriguez-Henriquez, P | 1 |
| Castillo-Martínez, D | 1 |
| Amezcua-Guerra, LM | 1 |
| Yang, X | 1 |
| Lv, H | 1 |
| Hidru, TH | 1 |
| Liu, H | 1 |
| Wang, Y | 1 |
| Liu, K | 1 |
| Xia, Y | 1 |
| Zhou, Y | 1 |
| Jiang, Y | 1 |
| Cho, YS | 1 |
| Bae, JH | 1 |
| Moon, SH | 1 |
| Hyun, SH | 1 |
| Choi, JY | 1 |
| Kim, BT | 1 |
| Lee, KH | 1 |
| Kiss, LZ | 1 |
| Bagyura, Z | 1 |
| Csobay-Novák, C | 1 |
| Lux, Á | 1 |
| Polgár, L | 1 |
| Jermendy, Á | 1 |
| Soós, P | 1 |
| Szelid, Z | 1 |
| Maurovich-Horvat, P | 1 |
| Becker, D | 1 |
| Merkely, B | 1 |
| Ahmad, MI | 1 |
| Dutta, A | 1 |
| Anees, MA | 1 |
| Soliman, EZ | 1 |
| Andrés, M | 2 |
| Bernal, JA | 1 |
| Arenas, MD | 1 |
| Pascual, E | 2 |
| Jeon, HJ | 1 |
| Oh, J | 1 |
| Shin, DH | 1 |
| Kawamura, Y | 1 |
| Nakaoka, H | 1 |
| Nakayama, A | 1 |
| Okada, Y | 1 |
| Yamamoto, K | 1 |
| Higashino, T | 1 |
| Sakiyama, M | 1 |
| Shimizu, T | 1 |
| Ooyama, H | 1 |
| Ooyama, K | 1 |
| Nagase, M | 1 |
| Hidaka, Y | 1 |
| Shirahama, Y | 1 |
| Hosomichi, K | 1 |
| Nishida, Y | 1 |
| Shimoshikiryo, I | 1 |
| Hishida, A | 1 |
| Katsuura-Kamano, S | 1 |
| Shimizu, S | 1 |
| Kawaguchi, M | 1 |
| Uemura, H | 1 |
| Ibusuki, R | 1 |
| Hara, M | 1 |
| Naito, M | 1 |
| Takao, M | 1 |
| Nakajima, M | 1 |
| Iwasawa, S | 1 |
| Nakashima, H | 1 |
| Ohnaka, K | 1 |
| Nakamura, T | 1 |
| Stiburkova, B | 1 |
| Merriman, TR | 1 |
| Nakatochi, M | 1 |
| Ichihara, S | 1 |
| Yokota, M | 1 |
| Takada, T | 1 |
| Saitoh, T | 1 |
| Kamatani, Y | 1 |
| Takahashi, A | 1 |
| Arisawa, K | 1 |
| Takezaki, T | 1 |
| Tanaka, K | 1 |
| Wakai, K | 1 |
| Kubo, M | 1 |
| Hosoya, T | 1 |
| Ichida, K | 1 |
| Inoue, I | 1 |
| Shinomiya, N | 1 |
| Matsuo, H | 1 |
| Lim, DH | 1 |
| Lee, Y | 1 |
| Park, GM | 1 |
| Choi, SW | 1 |
| Kim, YG | 2 |
| Lee, SW | 1 |
| Kim, YH | 1 |
| Yang, DH | 1 |
| Kang, JW | 1 |
| Lim, TH | 1 |
| Kim, HK | 1 |
| Choe, J | 1 |
| Hong, S | 1 |
| Lee, CK | 1 |
| Yoo, B | 1 |
| Liu, CW | 1 |
| Chang, WC | 1 |
| Lee, CC | 1 |
| Shau, WY | 1 |
| Hsu, FS | 1 |
| Wang, ML | 1 |
| Chen, TC | 1 |
| Lo, C | 1 |
| Hwang, JJ | 1 |
| Chatzipavlou, M | 1 |
| Magiorkinis, G | 1 |
| Koutsogeorgopoulou, L | 1 |
| Kassimos, D | 1 |
| Dohmen, K | 1 |
| Tanaka, H | 1 |
| Haruno, M | 1 |
| Duskin-Bitan, H | 1 |
| Cohen, E | 1 |
| Goldberg, E | 1 |
| Shochat, T | 1 |
| Levi, A | 1 |
| Garty, M | 1 |
| Krause, I | 1 |
| Perez-Ruiz, F | 2 |
| Castillo, E | 1 |
| Chinchilla, SP | 1 |
| Herrero-Beites, AM | 1 |
| Chen, JH | 1 |
| Wen, CP | 1 |
| Wu, SB | 1 |
| Lan, JL | 1 |
| Tsai, MK | 1 |
| Tai, YP | 1 |
| Lee, JH | 1 |
| Hsu, CC | 1 |
| Tsao, CK | 1 |
| Wai, JP | 1 |
| Chiang, PH | 1 |
| Pan, WH | 1 |
| Hsiung, CA | 1 |
| Fang, JI | 1 |
| Wu, JS | 1 |
| Yang, YC | 1 |
| Wang, RH | 1 |
| Lu, FH | 1 |
| Chang, CJ | 1 |
| Dalbeth, N | 1 |
| House, ME | 1 |
| Aati, O | 1 |
| Tan, P | 1 |
| Franklin, C | 1 |
| Horne, A | 1 |
| Gamble, GD | 1 |
| Stamp, LK | 1 |
| Doyle, AJ | 1 |
| McQueen, FM | 1 |
| Peluso, I | 1 |
| Teichner, A | 1 |
| Manafikhi, H | 1 |
| Palmery, M | 1 |
| Meng, J | 2 |
| Tan, W | 1 |
| Zhu, Y | 1 |
| Wang, F | 1 |
| Li, X | 1 |
| Zhang, M | 2 |
| Punzi, L | 1 |
| Takir, M | 1 |
| Kostek, O | 1 |
| Ozkok, A | 1 |
| Elcioglu, OC | 1 |
| Bakan, A | 1 |
| Erek, A | 1 |
| Mutlu, HH | 1 |
| Telci, O | 1 |
| Semerci, A | 1 |
| Odabas, AR | 1 |
| Afsar, B | 1 |
| Smits, G | 1 |
| ALanaspa, M | 1 |
| Sharma, S | 1 |
| Kanbay, M | 2 |
| Quintanilla, MA | 1 |
| Sivera, F | 1 |
| Sánchez-Payá, J | 1 |
| Vela, P | 1 |
| Ruiz-Nodar, JM | 1 |
| Breuer, GS | 1 |
| Bogot, N | 1 |
| Nesher, G | 1 |
| Rozza, F | 1 |
| Trimarco, V | 1 |
| Izzo, R | 1 |
| Grassi, D | 1 |
| Ferri, C | 1 |
| Nossent, J | 1 |
| Raymond, W | 1 |
| Divitini, M | 1 |
| Knuiman, M | 1 |
| Huang, Y | 1 |
| Sun, B | 1 |
| Xiang, T | 1 |
| Zhou, X | 1 |
| Xu, B | 1 |
| Wu, Y | 1 |
| Chen, Z | 1 |
| Zhang, S | 1 |
| Howard, RG | 1 |
| Pillinger, MH | 1 |
| Gyftopoulos, S | 1 |
| Thiele, RG | 1 |
| Swearingen, CJ | 1 |
| Samuels, J | 1 |
| Huddam, B | 1 |
| Azak, A | 1 |
| Solak, Y | 1 |
| Kadioglu, GK | 1 |
| Kirbas, I | 1 |
| Duranay, M | 1 |
| Covic, A | 1 |
| Oikonen, M | 1 |
| Wendelin-Saarenhovi, M | 1 |
| Lyytikäinen, LP | 1 |
| Siitonen, N | 1 |
| Loo, BM | 1 |
| Jula, A | 1 |
| Seppälä, I | 1 |
| Saarikoski, L | 1 |
| Lehtimäki, T | 1 |
| Hutri-Kähönen, N | 1 |
| Juonala, M | 1 |
| Kähönen, M | 1 |
| Huupponen, R | 1 |
| Viikari, JS | 1 |
| Raitakari, OT | 1 |
| Yakubov, R | 1 |
| Nir, V | 1 |
| Kassem, E | 1 |
| Klein-Kremer, A | 1 |
| Chang, H | 1 |
| Gao, Y | 1 |
| Wang, X | 1 |
| Xu, W | 1 |
| Liu, D | 1 |
| Li, G | 1 |
| Huang, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept[NCT04012294] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-08-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for uric acid and Asymptomatic Conditions
| Article | Year |
|---|---|
Asymptomatic hyperuricaemia: a silent activator of the innate immune system.
Topics: Asymptomatic Diseases; Biomarkers; Cytokines; Humans; Hyperuricemia; Immunity, Innate; Uric Acid | 2020 |
[Asymptomatic Hyperuricemia and Risk Of Cardiovascular and Renal Diseases].
Topics: Asymptomatic Diseases; Cardiovascular Diseases; Disease Progression; Humans; Hyperuricemia; Kidney D | 2020 |
Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout.
Topics: Adult; Aldehyde Dehydrogenase, Mitochondrial; Asymptomatic Diseases; ATP Binding Cassette Transporte | 2019 |
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Topics: Aged; Allopurinol; Asymptomatic Diseases; Biomarkers; Enzyme Inhibitors; Febuxostat; Female; Gout; G | 2019 |
Clinical manifestations and diagnosis of gout.
Topics: Asymptomatic Diseases; Chronic Disease; Disease Progression; Gout; Humans; Hyperuricemia; Uric Acid | 2014 |
Camellia sinensis in asymptomatic hyperuricemia: A meta-analysis of tea or tea extract effects on uric acid levels.
Topics: Antioxidants; Asymptomatic Diseases; Camellia sinensis; Cardiovascular Diseases; Dietary Supplements | 2017 |
5 trials available for uric acid and Asymptomatic Conditions
| Article | Year |
|---|---|
Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Carotid Artery Diseases; Carotid Intima-Media Thickn | 2020 |
Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia.
Topics: Adult; Aged; Allopurinol; Asymptomatic Diseases; Biomarkers; Female; Humans; Hyperuricemia; Inflamma | 2015 |
Effects of a Novel Fixed Combination of Nutraceuticals on Serum Uric Acid Concentrations and the Lipid Profile in Asymptomatic Hyperuricemic Patients : Results from the PICONZ-UA Study.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Dietary Supplements; Dr | 2016 |
Acupuncture for serum uric acid in patients with asymptomatic hyperuricemia: A randomized, double-blind, placebo-controlled trial.
Topics: Acupuncture Therapy; Adolescent; Adult; Aged; Asymptomatic Diseases; Biomarkers; Double-Blind Method | 2017 |
A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function.
Topics: Adult; Allopurinol; Analysis of Variance; Asymptomatic Diseases; Biomarkers; Blood Pressure; Blood P | 2011 |
40 other studies available for uric acid and Asymptomatic Conditions
| Article | Year |
|---|---|
Biomarkers and their relative contributions to identifying coronary artery stenosis based on coronary computed tomography angiography in asymptomatic adults.
Topics: Asymptomatic Diseases; Biomarkers; Computed Tomography Angiography; Coronary Stenosis; Cross-Section | 2019 |
Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities.
Topics: Age Factors; Aged; Asymptomatic Diseases; Biomarkers; China; Female; Heart Failure; Humans; Hyperuri | 2020 |
Predictive Factors for Kidney Stone Recurrence in Type 2 Diabetes Mellitus.
Topics: Aged; Asymptomatic Diseases; Body Mass Index; Calcium Oxalate; Causality; Cohort Studies; Comorbidit | 2020 |
Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Blood Pressure; Databases, Factual; Diastole; Disease Progr | 2020 |
Associations of serum uric acid level and gout with cardiac structure, function and sex differences from large scale asymptomatic Asians.
Topics: Adult; Asian People; Asymptomatic Diseases; Echocardiography, Doppler; Female; Gout; Heart Atria; He | 2020 |
Subclinical Heart Dysfunction in Relation to Metabolic and Inflammatory Markers: A Community-Based Study.
Topics: Asymptomatic Diseases; Atrial Function, Left; Belgium; Biomarkers; Blood Glucose; Echocardiography, | 2021 |
Performance of Ultrasound in the Clinical Evaluation of Gout and Hyperuricemia.
Topics: Adolescent; Adult; Aged; Arthritis, Gouty; Asymptomatic Diseases; Female; Gout; Humans; Hyperuricemi | 2021 |
Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.
Topics: Adolescent; Adult; Aged; Asymptomatic Diseases; Cohort Studies; Female; Gout; Gout Suppressants; Hum | 2021 |
To Treat or Not to treat Asymptomatic Hyperuricemia.
Topics: Asymptomatic Diseases; Gout; Gout Suppressants; Humans; Hyperuricemia; Uric Acid | 2021 |
Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease: A single-center cross-sectional study.
Topics: Adult; Aged; Asymptomatic Diseases; Coronary Artery Disease; Cross-Sectional Studies; Female; Humans | 2017 |
Relation of elevated serum uric acid levels to first-degree heart block and other cardiac conduction defects in hospitalized patients with type 2 diabetes.
Topics: Aged; Asymptomatic Diseases; Cardiac Conduction System Disease; Confounding Factors, Epidemiologic; | 2017 |
The association between serum uric acid and asymptomatic intracranial arterial stenosis in middle-aged Koreans.
Topics: Adult; Asymptomatic Diseases; Biomarkers; Comorbidity; Cross-Sectional Studies; Female; Humans; Hype | 2018 |
Serum Uric Acid Laboratory Test Request Patterns in Primary Care: How Panels May Contribute to Overutilization and Treatment of Asymptomatic Patients.
Topics: Asymptomatic Diseases; Blood Chemical Analysis; Cross-Sectional Studies; Humans; Laboratories; Medic | 2017 |
Hyperuricemia in Asian psoriatic arthritis patients.
Topics: Adult; Aged; Arthritis, Psoriatic; Asymptomatic Diseases; Biomarkers; Body Mass Index; Chi-Square Di | 2018 |
Maternal serum uric acid levels and blood pressure during pregnancy: A community-based cohort study.
Topics: Asymptomatic Diseases; Blood Pressure; Cohort Studies; Confounding Factors, Epidemiologic; Down-Regu | 2018 |
Uric Acid: The Lower the Better?
Topics: Asymptomatic Diseases; Glomerular Filtration Rate; Humans; Hyperuricemia; Randomized Controlled Tria | 2018 |
Systemic Implications of Hyperuricemia.
Topics: Asymptomatic Diseases; Energy Metabolism; Humans; Hyperuricemia; Nitrogen; Syndrome; Uric Acid | 2018 |
Levels of Cytokines and MicroRNAs in Individuals With Asymptomatic Hyperuricemia and Ultrasonographic Findings of Gout: A Bench-to-Bedside Approach.
Topics: Adult; Aged; Asymptomatic Diseases; Biomarkers; Case-Control Studies; Chronic Disease; Circulating M | 2018 |
Relation of serum uric acid to asymptomatic proximal extracranial artery stenosis in a middle-aged Chinese population: a community-based cross-sectional study.
Topics: Adult; Asian People; Asymptomatic Diseases; Biomarkers; Carotid Stenosis; China; Cohort Studies; Cro | 2018 |
Serum uric acid in asymptomatic adults is weakly associated with carotid artery FDG uptake but not intima-media thickness.
Topics: Adult; Asymptomatic Diseases; Atherosclerosis; Carotid Arteries; Carotid Intima-Media Thickness; Cro | 2020 |
Serum Uric Acid Is Independently Associated with Coronary Calcification in an Asymptomatic Population.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Computed Tomography Angiography; Coronary Angiography; Coro | 2019 |
Interrelations Between Serum Uric Acid, Silent Myocardial Infarction, and Mortality in the General Population.
Topics: Asymptomatic Diseases; Biomarkers; Cause of Death; Cross-Sectional Studies; Electrocardiography; Fem | 2019 |
Synovial fluid leukocyte count in asymptomatic hyperuricaemia with crystal deposition: a proof-of-concept study.
Topics: Aged; Asymptomatic Diseases; Crystallization; Female; Humans; Hyperuricemia; Leukocyte Count; Male; | 2019 |
Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Comorbidity; Female; Glomerular Filtration Rate; Humans; Hy | 2019 |
Serum uric acid level and subclinical coronary atherosclerosis in asymptomatic individuals: An observational cohort study.
Topics: Asymptomatic Diseases; Biomarkers; Computed Tomography Angiography; Coronary Angiography; Coronary A | 2019 |
Mediterranean diet intervention for patients with hyperuricemia: a pilot study.
Topics: Asymptomatic Diseases; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Diet, Me | 2014 |
Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Topics: Adult; Aged; Asymptomatic Diseases; Bezafibrate; Cardiovascular Diseases; Cholesterol, LDL; Cohort S | 2013 |
The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Asymptomatic Diseases; Cohort Studies; Female; Glo | 2014 |
Attenuating the mortality risk of high serum uric acid: the role of physical activity underused.
Topics: Adult; Aged; Asymptomatic Diseases; Cause of Death; Cohort Studies; Diabetes Mellitus; Exercise; Fem | 2015 |
High uric acid level associated with increased arterial stiffness in apparently healthy women.
Topics: Adult; Aged; Alcohol Drinking; Ankle Brachial Index; Anthropometry; Asymptomatic Diseases; Blood Glu | 2014 |
Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study.
Topics: Absorptiometry, Photon; Aged; Asymptomatic Diseases; Cross-Sectional Studies; Female; Foot; Foot Joi | 2015 |
A coronary artery disease-associated SNP rs6903956 contributed to asymptomatic hyperuricemia susceptibility in Han Chinese.
Topics: Asian People; Asymptomatic Diseases; Case-Control Studies; China; Coronary Artery Disease; Female; G | 2015 |
Hyperuricemia and tissue monourate deposits: prospective therapeutic considerations.
Topics: Asymptomatic Diseases; Cardiovascular Diseases; Cartilage; Gout; Humans; Hyperuricemia; Kidney Disea | 2015 |
Silent Monosodium Urate Crystal Deposits Are Associated With Severe Coronary Calcification in Asymptomatic Hyperuricemia: An Exploratory Study.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Coronary Artery Disease; Cross-Sectional Studies; Cr | 2016 |
Dual-energy computed tomography as a diagnostic tool for gout during intercritical periods.
Topics: Adult; Aged; Asymptomatic Diseases; Biomarkers; Female; Gout; Gout Suppressants; Humans; Joints; Mal | 2016 |
Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study.
Topics: Asymptomatic Diseases; Biomarkers; Cardiovascular Diseases; Female; Forecasting; Health Surveys; Hum | 2016 |
Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers.
Topics: Aged; Aged, 80 and over; Asymptomatic Diseases; Crystallization; Gout; Hospitals, Veterans; Humans; | 2011 |
Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study.
Topics: Adult; Age Factors; Asymptomatic Diseases; Atherosclerosis; Biomarkers; Body Mass Index; Cardiovascu | 2012 |
[Asymptomatic classical hereditary xanthinuria type 1].
Topics: Arabs; Asymptomatic Diseases; Child, Preschool; Diet Therapy; Disease Management; Female; Humans; In | 2012 |
Major dietary patterns and risk of asymptomatic hyperuricemia in Chinese adults.
Topics: Adult; Asian People; Asymptomatic Diseases; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL | 2012 |